
In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.

In this interview we discuss results of the PlanB trial, which showed that use of the 21-gene recurrence score, Oncotype DX, can identify patients with early breast cancer who likely do not need chemotherapy.